We advised GSK on the transaction

Davis Polk advised GSK in connection with its strategic research, collaboration and license agreement with CAMP4 Therapeutics Corporation. Under the agreement, CAMP4 will utilize its proprietary RAP Platform to identify regRNAs controlling the expression of multiple gene targets relevant to neurodegenerative and kidney disease indications and generate regRNA-targeting antisense oligonucleotide (ASO) candidates that amplify target gene expression for potential development. GSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration. CAMP4 will receive a $17.5 million cash upfront payment and has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

CAMP4 is a clinical-stage biopharmaceutical company developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits.

The Davis Polk IP and commercial transactions team included partner David R. Bauer, counsel Samantha Lefland and associate Ted (Edward) Talas. Partner William A. Curran and associate Fred (Chen) Fu provided tax advice. The antitrust and competition team included partners Jesse Solomon and Matthew Yeowart, counsel Meytal McCoy and associate Andrzej O’Leary. Members of the Davis Polk team are based in the New York, Washington DC and London offices.

Copy link to share post